![]() |
Name |
4-Oxo-1,4-dihydro-quinoline-3-carboxamide
|
Molecular Formula | C10H8N2O2 | |
IUPAC Name* |
4-oxo-1H-quinoline-3-carboxamide
|
|
SMILES |
C1=CC=C2C(=C1)C(=O)C(=CN2)C(=O)N
|
|
InChI |
InChI=1S/C10H8N2O2/c11-10(14)7-5-12-8-4-2-1-3-6(8)9(7)13/h1-5H,(H2,11,14)(H,12,13)
|
|
InChIKey |
CVAWACBLSANHSQ-UHFFFAOYSA-N
|
|
Synonyms |
4-oxo-1,4-dihydroquinoline-3-carboxamide; 4-oxo-1H-quinoline-3-carboxamide; 4-oxo-1,4-dihydro-quinoline-3-carboxamide; 103914-79-0; SCHEMBL1165508; 4-hydroxyquinoline-3-carboxamide; 4-hydroxy-3-quinoline carboxamide; ZINC8691828; AKOS009358267; EN300-250668; Z394696406
|
|
CAS | NA | |
PubChem CID | 824670 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 188.18 | ALogp: | 1.2 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 72.2 | Aromatic Rings: | 2 |
Heavy Atoms: | 14 | QED Weighted: | 0.701 |
Caco-2 Permeability: | -4.853 | MDCK Permeability: | 0.00000705 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.99 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.982 |
Blood-Brain-Barrier Penetration (BBB): | 0.996 | Plasma Protein Binding (PPB): | 65.67% |
Volume Distribution (VD): | 1.132 | Fu: | 54.42% |
CYP1A2-inhibitor: | 0.933 | CYP1A2-substrate: | 0.337 |
CYP2C19-inhibitor: | 0.196 | CYP2C19-substrate: | 0.062 |
CYP2C9-inhibitor: | 0.057 | CYP2C9-substrate: | 0.797 |
CYP2D6-inhibitor: | 0.082 | CYP2D6-substrate: | 0.401 |
CYP3A4-inhibitor: | 0.043 | CYP3A4-substrate: | 0.126 |
Clearance (CL): | 3.303 | Half-life (T1/2): | 0.238 |
hERG Blockers: | 0.055 | Human Hepatotoxicity (H-HT): | 0.158 |
Drug-inuced Liver Injury (DILI): | 0.806 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.636 | Maximum Recommended Daily Dose: | 0.053 |
Skin Sensitization: | 0.508 | Carcinogencity: | 0.091 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.94 |
Respiratory Toxicity: | 0.196 |